United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 4 minute read Healthcare Industry News Summit Clinical Research doubles down on liver disease trials with Houston Research Institute deal and top-level hires Find out how Summit Clinical Research is expanding its metabolic research leadership with the acquisition of Houston Research Institute and new executive hires. byPallavi MadhirajuMay 1, 2025